How to Buy Vyne Therapeutics Stock
Vyne Therapeutics Inc
VYNE Therapeutics Inc. , a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions.
Vyne Therapeutics stock last closed at $1.79, down 3.24% from the previous day, and has decreased 23.83% in one year. It has overperformed other stocks in the Biotechnology industry by 0.54 percentage points. Vyne Therapeutics stock is currently +24.31% from its 52-week low of $1.44, and -58.37% from its 52-week high of $4.30.
As of Apr 21, 2025, there are 15.21M shares of VYNE outstanding. The market cap of VYNE is $27.23M. In the past 24 hours, 59,167 VYNE shares were traded.
How to Buy Vyne Therapeutics Stock
Wondering how to invest in Vyne Therapeutics stock? Here's how.
- Decide where to buy Vyne Therapeutics stock: You need to pick an online brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you figure out where to buy Vyne Therapeutics stock.
- Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Put funds into your investment account: Choose your payment method and add your details.
- Research Vyne Therapeutics stock: The Vyne Therapeutics ticker symbol is VYNE. Is Vyne Therapeutics stock a good investment? Should you buy shares of VYNE? How do VYNE's underlying business fundamentals look? Do top analysts think Vyne Therapeutics is a good buy? Why has VYNE's stock price moved recently? (Hint: Our stock research website can help you evaluate if VYNE is a good stock to buy).
- Execute your VYNE trade: Decide if you will purchase VYNE shares at the current market price or use a limit order to purchase VYNE shares at a given price.
- Get notifications regarding your VYNE position: Create a watchlist to key updates about your new investment in Vyne Therapeutics shares.
Step 1: Decide where to buy Vyne Therapeutics stock
You need an online brokerage account in order to access the NASDAQ market and buy VYNE stock.
Our preferred brokerage: eToro
Based on our experience, eToro is the best brokerage. Here's why:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to global markets: From Tech to Healthcare, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro has a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've picked the right brokerage, the next step is to fill out some personal information so you can invest in VYNE stock today.
How to Open a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal info to open a new brokerage account.
- Send your application by pressing the "Create Account" button. Get started with eToro today
Step 3: Put funds into your investment account
Now that you have finished signing up on one of the most highly reviewed stock market apps, you can securely and quickly fund your account:
Check out this video walkthrough to see the process of transferring money into your new brokerage account.
Step 4: Research Vyne Therapeutics stock
Once you have selected the best place to buy Vyne Therapeutics stock, it's absolutely critical to evaluate their stock before you invest, so you actually understand the risk as well as the opportunity.
Vyne Therapeutics Metrics
Vyne Therapeutics Due Diligence Score
WallStreetZen was built to help everyday investors do better fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on VYNE's stock page.
How is VYNE stock valued?
You can use many financial metrics, analyses, models, and charts to gauge VYNE's intrinsic value.
Using relative valuations ratios:
- VYNE could be undervalued based on its P/B ratio of 0.52x, relative to Biotechnology industry P/B ratio of 4.04x
You can do more valuation analysis on VYNE's stock here.
How do VYNE Financials look?
Passed Health Checks:
- VYNE has $61.52M in cash and short term investments. This is sufficient to cover its annual cash burn of $34.09M.
- There are more short-term assets than long-term liabilities on the VYNE balance sheet.
- VYNE has a low debt to equity ratio of 0.29.
- Total VYNE debt is lower than 5 years ago, relative to shareholder equity.
- VYNE has cash burn of 34089000. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the VYNE balance sheet.
Failed Health Checks:
- VYNE profit margin has gone down from -6,710.4% to -7,950.9% in the past year.
Do analysts think it's a good time to buy VYNE stock
Out of 2 sell side analysts who give forecasts on VYNE, the consensus analyst rating on VYNE is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they investment advice.
You can dive deeper into what analysts are saying on the Vyne Therapeutics stock forecast page.
VYNE Trading Indicators
VYNE Growth Metrics
Last year, VYNE revenue was $501.00k. Over the past five year, VYNE's revenue has grown by 2.49% per year. This was slower than the Biotechnology industry average of 44.31%.
You can analyze VYNE's earnings and revenue performance here.
Who is buying/selling VYNE?
In the past 12 months, insiders at VYNE have sold more shares than they have bought.
David Domzalski, PRESIDENT AND CEO of VYNE, was the latest VYNE insider to sell. They sold $48,186.84 worth of VYNE shares on Mar 31, 2025.
Get more info about who owns VYNE shares here.
Can I rely on VYNE as an income stream?
No, Vyne Therapeutics doesn't provide an income stream by paying out dividends.
VYNE Social Trading Data
One of the biggest reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other traders have to say.
Step 5: Execute your VYNE trade
There are two main order types:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are generally the easiest way to buy. - Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at a given dollar amount limit, use a limit order.
Hit the Open button and your broker will place the order.
If you want additional help investing in stocks on eToro, watch the how to video below:
Step 6: Get notifications regarding your VYNE position
Now that you own some VYNE stock, you'll want to stay up-to-date on your new shares.
Add VYNE to a watchlist to track your VYNE stock.
VYNE Feed
How to Buy Stock in Vyne Therapeutics
To summarize, here are the 6 steps to buy stock in Vyne Therapeutics:
- Decide where to buy Vyne Therapeutics stock
- Open a brokerage account
- Put funds into your investment account
- Research Vyne Therapeutics stock
- Execute your VYNE trade
- Get notifications regarding your VYNE position
If you require a place to buy stocks, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to track your investment in Vyne Therapeutics, add VYNE to your watchlist by clicking the button below.
Trending Content
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.